GleamWall
中文EN

UNCY Unicycive Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1766140 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-8.4%
TTM EPS YoY53.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-80.4%
ROA-60.1%
ROIC (approx.)-1,005.6%
Asset turnover—

Leverage & solvency

Liabilities / assets24.8%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$9.12M$20.01M
SG&A expense$20.40M$12.10M
Operating income-$29.52M-$32.12M
Interest expense$71,000$71,000
Net income-$26.55M-$36.73M
EBITDA-$29.48M-$32.09M
EPS (basic)-1.67-5.65
EPS (diluted)-1.67-5.65
Weighted avg. shares (diluted)15.89M6.70M
Balance sheet
Cash & equivalents$29.20M$26.14M
Short-term investments$12.07M—
Current assets$48.96M$30.95M
PP&E, net$66,000$75,000
Total assets$49.13M$31.67M
Current liabilities$18.94M$24.12M
Total liabilities$18.94M$24.24M
Shareholders' equity$30.20M$7.43M
Shares outstanding22.11M11.38M
Cash flow statement
Operating cash flow-$31.32M-$28.57M
Capital expenditure$24,000$72,000
Free cash flow-$31.34M-$28.65M
Investing cash flow-$12.10M-$72,000
Financing cash flow$46.47M$45.09M
Depreciation & amortization$34,000$22,000
Stock-based compensation$2.64M$2.35M
Dividends paid—$1.09M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.